Patient-Oriented Evidence That Matters

Screening for Ovarian Cancer with CA 125 and Ultrasound Algorithm Does Not Reduce Mortality


Am Fam Physician. 2021 Oct ;104(4):422-423.

Clinical Question

Does screening for ovarian cancer using an algorithm that customizes interpretation and follow-up of cancer antigen (CA) 125 testing reduce ovarian cancer mortality in average-risk women?

Bottom Line

Like the U.S. Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, this large and long U.K. study found no reduction in ovarian cancer mortality with screening using ultrasonography or a multimodal CA 125–based screening strategy. (Level of Evidence = 1b)


The U.K. Collaborative Trial of Ovarian Cancer Screening was a randomized trial that recruited approximately 200,000 average-risk women 50 to 74 years of age. They were randomized in a 1:1:2 ratio to multimodal screening, annual ultrasonography, or usual care. Multimodal screening was based on CA 125 testing, but instead of a single cutoff for all women, there were individualized cutoffs. Significant changes from each woman's baseline triggered additional blood tests and if necessary, ultrasonography and biopsy. Women were recruited between 2001 and 2005 and were screened regularly until 2011. An interim report of this trial after a median of 11 years of follow-up initially claimed to have detected a reduction in disease-specific mortality in a post-hoc analysis of incomplete data. This interpretation was criticized in an editorial from the Ovarian Cancer Research Fund Alliance and the Banbury Conference Writing Group because the investigators have a financial stake in the patented CA 125 algorithm. The results in the full report are based on follow-up for a median of 16.3 years with complete follow-up for 95% of the cohort. Overall, 0.9% of women in each group were given a diagnosis of invasive epithelial ovarian or tubal cancer. There was no significant difference between groups in ovarian cancer–specific mortality (0.58% in the multimodal screening group vs. 0.61% in the control group; P = 0.58). Secondary analyses looking at only early and late deaths found no difference in mor

POEMs (patient-oriented evidence that matters) are provided by Essential Evidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.

For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.

To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.

This series is coordinated by Sumi Sexton, MD, editor-in-chief.

A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.



Want to use this article elsewhere? Get Permissions

CME Quiz

More in AFP

Editor's Collections

Related Content


Nov 2021

Access the latest issue of American Family Physician

Read the Issue

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article